Amit Akirov1,2, Hiba Masri-Iraqi3,4, Alexander Gorshtein3,4, Hadar Duskin-Bitan3,4, Keren Kaminer3,4, Ilan Shimon3,4. 1. Institute of Endocrinology, Beilinson Hospital, Petah Tikva, Israel. amit.akirov@gmail.com. 2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. amit.akirov@gmail.com. 3. Institute of Endocrinology, Beilinson Hospital, Petah Tikva, Israel. 4. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
AIM: The aim of this study is to assess the benefits of a nurse-led home injection service for somatuline autogel-treated patients with acromegaly, including the adherence to treatment and disease control. METHODS: Historical prospective data of all patients with acromegaly initiating somatuline autogel between November 14, 2000, and March 9, 2020, who voluntarily enrolled in the nurse-led home injection service between January 1, 2018 and June 30, 2020. Adherence to treatment was calculated as the number of administered injections divided by the number of expected injections during the follow-up period. Excellent adherence to treatment was defined when >90% of scheduled injections were administered, while low adherence was defined when patients received <80% of expected injections. The primary outcome was the adherence to treatment. RESULTS: The cohort included 88 patients (mean age ± SD, 59.8 ± 14.9 years, 53% men). Average adherence to treatment was 93 ± 8% (range 62-100%). Excellent adherence was documented in 65 participants (74%), of which 29 patients (33%) received all scheduled injections. Low adherence to treatment was recorded in seven patients (8%). Average adherence was high independent of gender, age, prior surgery, or radiation therapy, or whether somatuline autogel was used as monotherapy or in combination regimens. However, excellent adherence decreased with increased somatuline dose and with dosing interval of 21 days. Average adherence was slightly higher in patients with biochemically controlled acromegaly. CONCLUSIONS: A nurse-led home injection service for somatuline autogel injections is associated with high adherence to treatment. Establishing such a program globally may lead to better adherence to treatment and improved disease control.
AIM: The aim of this study is to assess the benefits of a nurse-led home injection service for somatuline autogel-treated patients with acromegaly, including the adherence to treatment and disease control. METHODS: Historical prospective data of all patients with acromegaly initiating somatuline autogel between November 14, 2000, and March 9, 2020, who voluntarily enrolled in the nurse-led home injection service between January 1, 2018 and June 30, 2020. Adherence to treatment was calculated as the number of administered injections divided by the number of expected injections during the follow-up period. Excellent adherence to treatment was defined when >90% of scheduled injections were administered, while low adherence was defined when patients received <80% of expected injections. The primary outcome was the adherence to treatment. RESULTS: The cohort included 88 patients (mean age ± SD, 59.8 ± 14.9 years, 53% men). Average adherence to treatment was 93 ± 8% (range 62-100%). Excellent adherence was documented in 65 participants (74%), of which 29 patients (33%) received all scheduled injections. Low adherence to treatment was recorded in seven patients (8%). Average adherence was high independent of gender, age, prior surgery, or radiation therapy, or whether somatuline autogel was used as monotherapy or in combination regimens. However, excellent adherence decreased with increased somatuline dose and with dosing interval of 21 days. Average adherence was slightly higher in patients with biochemically controlled acromegaly. CONCLUSIONS: A nurse-led home injection service for somatuline autogel injections is associated with high adherence to treatment. Establishing such a program globally may lead to better adherence to treatment and improved disease control.
Authors: Cristina Álvarez-Escolá; Eva María Venegas-Moreno; Juan Antonio García-Arnés; Concepción Blanco-Carrera; Mónica Marazuela-Azpiroz; María Ángeles Gálvez-Moreno; Edelmiro Menéndez-Torre; Javier Aller-Pardo; Isabel Salinas-Vert; Eugenia Resmini; Elena María Torres-Vela; María Ángeles Gonzalo-Redondo; Ricardo Vílchez-Joya; María Paz de Miguel-Novoa; Irene Halperín-Rabinovich; Concepción Páramo-Fernández; Guillermo de la Cruz-Sugranyes; Aude Houchard; Antonio Miguel Picó-Alfonso Journal: Endocrinol Diabetes Nutr (Engl Ed) Date: 2019-02-14 Impact factor: 1.417
Authors: J Schopohl; C J Strasburger; D Caird; K Badenhoop; F Beuschlein; M Droste; U Plöckinger; S Petersenn Journal: Exp Clin Endocrinol Diabetes Date: 2010-11-17 Impact factor: 2.949
Authors: Laurence Katznelson; Edward R Laws; Shlomo Melmed; Mark E Molitch; Mohammad Hassan Murad; Andrea Utz; John A H Wass Journal: J Clin Endocrinol Metab Date: 2014-10-30 Impact factor: 5.958
Authors: Kathryn E O'Reilly; Fredi Rojo; Qing-Bai She; David Solit; Gordon B Mills; Debra Smith; Heidi Lane; Francesco Hofmann; Daniel J Hicklin; Dale L Ludwig; Jose Baselga; Neal Rosen Journal: Cancer Res Date: 2006-02-01 Impact factor: 12.701